Filter Results:
(110)
Show Results For
- All HBS Web
(284)
- News (112)
- Research (110)
- Events (1)
- Multimedia (3)
- Faculty Publications (36)
Show Results For
- All HBS Web
(284)
- News (112)
- Research (110)
- Events (1)
- Multimedia (3)
- Faculty Publications (36)
Sort by
- 06 Sep 2006
- Lessons from the Classroom
Mixing Students and Scientists in the Classroom
niche." His on-going research at HBS synthesizes elements of history, sociology, business, and statistics. In the classroom, Fleming has carved out a place for himself helping students from diverse disciplines learn to work together... View Details
- May 2021
- Article
Value-Based Healthcare in Urology: A Collaborative Review
By: Chanan Reitblat, Paul A. Bain, Michael E. Porter, David N. Bernstein, Thomas W. Feeley, Markus Graefen, Santosh Iyer, Matthew J. Resnick, C.J. Stimson, Quoc-Dien Trinh and Boris Gershman
Context:
In response to growing concerns over rising costs and major variation in quality, improving value for patients has been proposed as a fundamentally new strategy for how healthcare should be delivered, measured, and... View Details
In response to growing concerns over rising costs and major variation in quality, improving value for patients has been proposed as a fundamentally new strategy for how healthcare should be delivered, measured, and... View Details
Keywords: Value-based Healthcare; Integrated Practice Units; Outcome Measurement; Time-Driven Activity-Based Costing; Health Care and Treatment; Value; Cost Management; Strategy; Outcome or Result; Measurement and Metrics
Reitblat, Chanan, Paul A. Bain, Michael E. Porter, David N. Bernstein, Thomas W. Feeley, Markus Graefen, Santosh Iyer, Matthew J. Resnick, C.J. Stimson, Quoc-Dien Trinh, and Boris Gershman. "Value-Based Healthcare in Urology: A Collaborative Review." European Urology 79, no. 5 (May 2021): 571–585.
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- December 2019
- Technical Note
Technical Note on Bayesian Statistics and Frequentist Power Calculations
By: Amitabh Chandra and Ariel Dora Stern
This Technical Note provides an introduction to Bayes’ Rule and the statistical intuition that stems from it. In this note, we review the concepts that underlie Bayesian statistics, and we offer several simple mathematical examples to illustrate applications of Bayes’... View Details
Chandra, Amitabh, and Ariel Dora Stern. "Technical Note on Bayesian Statistics and Frequentist Power Calculations." Harvard Business School Technical Note 620-032, December 2019.
- August 2023
- Case
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company
By: Satish Tadikonda and Brad Prosek
Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details
Keywords: Mergers and Acquisitions; Health Care and Treatment; Organizational Change and Adaptation; Research and Development; Business Strategy; Partners and Partnerships; Goals and Objectives; Pharmaceutical Industry; United States
Tadikonda, Satish, and Brad Prosek. "Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company." Harvard Business School Case 824-032, August 2023.
- 22 Mar 2021
- Research & Ideas
How to Learn from the Big Mistake You Almost Make
Steinberg, and Ann Raldow, and medical physicist Nzhde Agazaryan. A spectrum of close calls The research team wanted to understand the role of psychological safety—defined as “the shared belief that interpersonal risk-taking is safe”—in... View Details
- 22 Feb 2022
- Research & Ideas
Lack of Female Scientists Means Fewer Medical Treatments for Women
Women are more likely to invent medical treatments for endometriosis, cervical cancer, and other female conditions, but the dearth of women scientists limits the potential for such life-saving innovations. Female research teams are 35... View Details
Keywords: by Kristen Senz
- March 2021 (Revised January 2023)
- Case
The Trouble with TCE
By: Vincent Pons, Rafael Di Tella and Galit Goldstein
Trichloroethylene, or TCE, was a chemical used by tens of thousands of businesses in the United States. It was an affordable tool for many. Yet, TCE had been associated with important health risks, including cancer and autoimmune disease. TCE potentially posed other... View Details
Keywords: Trichloroethylene; Toxicity; Lobbying; Chemicals; Health Disorders; Governing Rules, Regulations, and Reforms; Policy; Ethics; Business and Government Relations; Chemical Industry; United States
Pons, Vincent, Rafael Di Tella, and Galit Goldstein. "The Trouble with TCE." Harvard Business School Case 721-031, March 2021. (Revised January 2023.)
- 16 Sep 2019
- Research & Ideas
Crowdsourcing Is Helping Hollywood Reduce the Risk of Movie-Making
writer based in the Boston area. [Image: CasarsaGuru] Related Reading: Related Reading Black Business Leaders Series: Franklin Leonard, 'Black List' Mastermind Should Entrepreneurs Pitch Products or Ideas for Products? Open Innovation Contestants Build AI-Based View Details
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- March 2008 (Revised June 2008)
- Case
The Broad Institute: Applying the Power of Genomics to Medicine
By: Vicki L. Sato and Rachel Gordon
In June 2003, Harvard University and MIT announced an unprecedented partnership to create a biomedical institute, The Broad Institute. The culture of the Broad centered on science, and those involved considered it to be at the edge of the scientific frontier. In just... View Details
Keywords: Education; Health Care and Treatment; Innovation Leadership; Growth and Development Strategy; Organizational Culture; Partners and Partnerships; Research and Development; Genetics
Sato, Vicki L., and Rachel Gordon. "The Broad Institute: Applying the Power of Genomics to Medicine." Harvard Business School Case 608-114, March 2008. (Revised June 2008.)
- 14 Dec 2020
- Research & Ideas
What Does December's Drug-Approval Dash Mean for COVID-19 Vaccines?
Pharmaceutical regulators around the world tend to speed through drug applications in December and before major national holidays, according to new research that might raise questions about COVID-19 vaccines and other treatments under... View Details
- 12 Dec 2022
- Research & Ideas
Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them
Black patients and their doctors may be more open to new medications if drug trials included more Black people, new research shows. Currently, Black Americans represent just 5 percent of drug trial participants. Nearly three-quarters of... View Details
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
In economic downtimes, businesses are apt to cut R&D projects that don't promise a speedy return on investment. But take a cue from smart science-based businesses, which view the recession as an opportunity to stoke up research and... View Details
- 20 Sep 2016
- First Look
September 20, 2016
growing body of research yields ample evidence that individuals’ behavior often reflects an apparent concern for moral considerations. Using a broad definition of morality—to include varied non-egoistic motivations such as fairness,... View Details
Keywords: Sean Silverthorne
- 30 Apr 2024
- Book
When Managers Set Unrealistic Expectations, Employees Cut Ethical Corners
In the 1990s, when Harvard Business School Professor Lynn S. Paine was researching and writing about examples of corporate misconduct, she hoped more businesses would take decisive action to root out fraud and other unethical behavior.... View Details
Keywords: by Dina Gerdeman
- 26 Jan 2015
- Research & Ideas
National Health Costs Could Decrease if Managers Reduce Work Stress
research that shows workplace stress is very bad for health, and we have this other information that says our health costs are way above that of other countries," says Joel Goh, Harvard Business School assistant professor of business... View Details
- 03 Oct 2023
- Research Event
Build the Life You Want: Arthur Brooks and Oprah Winfrey Share Happiness Tips
specifically his descriptions of the manifold research that's going on on happiness, did you yourself change your own definition of what happiness is? What did you what did you learn or change? Winfrey: What I learned is that days where... View Details
Keywords: by HBS Staff